OMERS investments steady in a difficult market environment
Retrieved on:
Thursday, August 18, 2022
Knowledge, Medicine, Sony Centre, Investment, Data management, Annual report, Patient, TPG Telecom, Health, Electricity, CompTIA, Shipyard, Update, Control, Risk, Industry, Technology, Administration, Bionics, Burosumab, Partnership, Biotechnology, Water, Physician, Midland Cogeneration Venture, OMERS, Interim, Glass, Navy Yard, Royal Bank Plaza, List, District, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Acquisition, HVAC, Maintenance, Practice management, Solution, Moves, SME, Confederation Bridge, AGP, Transport, Automation, Financial statement, Insurance, Confederation, MCV, Adult, Bank, Fine chemical, Health insurance, Online gambling, Pharmaceutical industry, Renewable energy, Mobile phone, Birdy
OMERS Administration Corporations financial performance set out in this Investment Update is only for the period ended June 30, 2022.
Key Points:
- OMERS Administration Corporations financial performance set out in this Investment Update is only for the period ended June 30, 2022.
- The financial information included in this Investment Update should be read in conjunction with the Interim Financial Statements.
- To create value for our members over the long term, OMERS remains focused on strengthening our portfolio and deploying capital towards our target asset mix.
- We believe that investments centred around life sciences and health care make a meaningful difference today, as they support and advance innovative solutions for tomorrows medical needs.